Speaker illustration

Professor Michael Holinstat

University of Michigan, Ann Arbor (United States of America)

Dr. Michael Holinstat began his career as an assistant professor at Thomas Jefferson University in Philadelphia in 2009. In 2015, Dr. Holinstat moved his research lab to the University of Michigan where he is now a Professor in the department of Pharmacology and is a fellow of the American Heart Association. Dr. Holinstat’s research interests focus on understanding platelet signaling and function and how it relates to regulation of hemostasis and thrombosis with an emphasis on discovery of novel oxylipin and lipoxygenase targets in the platelet for the development of new therapeutic drugs for the treatment of cardiovascular diseases. Dr. Holinstat has received several national awards including the Kenneth M. Brinkhous Young Investigator Prize in Thrombosis from American Heart Association and the Young investigator Award in Structure-Function from the Eicosanoid Research Foundation. On a personal note, Dr. Holinstat is an avid trophy fisherman.

HDAC inhibitor CS014 inhibits platelet activity, small and large vessel thrombosis while maintaining haemostasis in a dose-dependent manner

Event: ESC Congress 2023

Topic: Antiplatelet Drugs

Session: Current and novel antiplatelet therapy in cardiovascular disease


CS014 is a novel HDAC inhibitor regulating the platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding

Event: ESC Congress 2022

Topic: Antiplatelet Drugs

Session: Challenges and advances in antithrombotic therapy


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb